Quantitative histopathology for cancer prognosis using quantitative phase imaging on stained tissues
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3R01CA238191-02S1
Grant search
Key facts
Disease
COVID-19Start & end year
20212022Known Financial Commitments (USD)
$576,268Funder
National Institutes of Health (NIH)Principal Investigator
Gabriel PopescuResearch Location
United States of AmericaLead Research Institution
University Of Illinois At Urbana-ChampaignResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
Innovation
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Summary Fast, accurate, and scalable testing has been recognized unanimously as crucial for mitigating the impact of COVID-19 and future pandemics. We propose a technology that allows rapid (~2 minutes) testing for SARS CoV-2. Our technology combines novel label-free imaging and dedicated deep-learning algorithms to detect and classify viral populations in exhaled air. If successful, this project will result in a device based on quantitative phase imaging and integrated AI tools, which will detect the unlabeled virus acquired by the patient's breath condensed on a microscope slide. Toward this goal, we will advance Spatial Light Interference Microscopy (SLIM), an ultrasensitive label-free imaging technique, proven to measure structures down to the sub-nanometer scale. SLIM was developed in the PI's Lab at UIUC, its original publication received 490 citations to date, and has been commercialized by Phi Optics (Research Park, UIUC), with sales across the world in both academia and industry. Applying the computed fluorescence maps back to the QPI data, we propose to measure nanoscale features of viral particles, with high specificity, minimal preparation time, and independent of clinical infrastructure. As a result, the new technology will eventually be ideal for point-of-care settings, surveillance screening and as a home monitoring device. We anticipate that our approach will be scalable to other viruses, with new imaging and training data.